A three-dose course of AstraZeneca’s COVID-19 vaccine is effective against the rapidly-spreading Omicron coronavirus variant, the pharmaceutical company said on Thursday, citing data from an Oxford University lab study.
Findings from the study, yet to be published in a peer-reviewed medical journal, match those from rivals Pfizer-BioNTech and Moderna which have also found a third dose of their shots works against Omicron.
The study on AstraZeneca’s vaccine, Vaxzevria, showed that after a three-dose course of the vaccine, neutralising levels against Omicron were broadly similar to those against the virus’s Delta variant after two doses.
The London-listed company said researchers at Oxford University who carried out the study were independent from those who worked on the vaccine with AstraZeneca.
“As we better understand Omicron, we believe we will find that T-cell response provides durable protection against severe disease and hospitalisations,” Mene Pangalos, the head of AstraZeneca’s biopharmaceuticals R&D said, referring to a critical component of the immune system that respond to fight infection.
Antibody levels against Omicron after the booster shot were higher than antibodies in people who had been infected with and recovered naturally from COVID-19, the Anglo-Swedish drugmaker added.
